|
|
| | Taurohyodeoxycholic acid sodium salt Basic information |
| Product Name: | Taurohyodeoxycholic acid sodium salt | | Synonyms: | Sodium taurohyodeoxycholate hydrate;taurohyodeoxycholic acid sodium hydrate;SODIUM TAUROHYODEOXYCHOLATE;5-BETA-CHOLANIC ACID-3-ALPHA, 6-ALPHA-DIOL N-(2-SULPHOETHYL)-AMIDE SODIUM SALT;Taurodeoxychloic Acid sodium hydrate;taurohyodeoxycholic acid sodium;Taurodeoxycholic acid sodium,Inhibitor,Taurodeoxycholic acid sodium hydrate,Sodium taurodeoxycholate,Caspase,Apoptosis,inhibit;5β-CHOLANIC ACID-3α, 6α-DIOL N-(2-SULPHOETHYL)-AMIDE SODIUM SALT | | CAS: | 110026-03-4 | | MF: | C26H44NNaO6S | | MW: | 521.69 | | EINECS: | 206-132-7 | | Product Categories: | | | Mol File: | 110026-03-4.mol |  |
| | Taurohyodeoxycholic acid sodium salt Chemical Properties |
| Melting point | 168 °C (dec.)(lit.) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | H2O: 0.1 g/mL, clear, colorless to very faintly yellow | | form | Solid | | color | White to Off-White |
| | Taurohyodeoxycholic acid sodium salt Usage And Synthesis |
| Uses | A bile acid which stimulates the flow of bile salts, for potential treatment of Irritable Bile Syndrome. | | in vivo | Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[1]. | Animal Model: | C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis[1] | | Dosage: | 0.5 mg/kg | | Administration: | Intravenous injection, 30 min or 24 h after LPS injection | | Result: | Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice. |
| | IC 50 | Microbial Metabolite |
| | Taurohyodeoxycholic acid sodium salt Preparation Products And Raw materials |
|